8-K: Sanuwave Refinances Debt, Secures $28M J.P. Morgan Credit Facility

Sanuwave Health, Inc. announced a strategic debt refinancing, replacing its $27.5 million facility with a new $28 million credit facility from J.P. Morgan, reducing overall debt and interest rates.

Summary

• Sanuwave Health, Inc. entered into a new credit agreement with JPMorgan Chase Bank, N.A. on September 25, 2025.
• The new facility includes a $23.0 million secured term loan maturing on September 25, 2029, and a $5.0 million secured revolving credit facility maturing on September 25, 2027.
• Interest on both the term loan and revolver accrues at a rate of SOFR + 3.50% per annum or base rate + 2.50% per annum, at the company's option.
• The company drew approximately $1.0 million from the revolving credit facility at closing, resulting in total outstanding debt of approximately $24.0 million under the new facility.
• Proceeds from the new facility, along with cash on hand, were used to repay all outstanding indebtedness and obligations under the previous $27.5 million Note and Warrant Purchase and Security Agreement (NWPSA) with NH Expansion Credit Fund Holdings LP.
• The remaining $3.5 million owed on the NH Expansion debt and approximately $1.3 million in transaction and initiation costs were paid using cash from operations and the sale of certain intravascular shockwave patents.
• The new facility allows for prepayments at any time without premium or penalty, subject to customary breakage costs for Term SOFR loans.
• The company is subject to financial covenants including a maximum total leverage ratio of 2.50 to 1.00 and a minimum fixed charge coverage ratio of 1.25 to 1.00, calculated quarterly on a consolidated basis.

Sentiment

Score: 8

Explanation: The refinancing significantly improves the company's financial structure by reducing overall debt, lowering interest costs, and eliminating prepayment penalties, which are strong positive indicators for financial health and operational flexibility. The partnership with J.P. Morgan also adds credibility.

Positives

• Significant reduction in the company's overall debt load from $27.5 million to $24.0 million.
• Reduced interest rate (though the previous rate is not specified, management states a "significant reduction").
• New credit facility has no prepayment penalties, offering financial flexibility.
• Secured a credit facility with J.P. Morgan, a globally recognized financial institution.
• Improved financial position to better generate cash flow for debt repayment from operations.

Negatives

• New debt is secured by a lien on substantially all tangible and intangible assets of the company and its guarantors.
• The revolving credit facility is subject to a borrowing base composed of eligible accounts receivable, which could limit availability.

Risks

• Risks associated with regulatory oversight.
• Risks related to the company's ability to manage its capital resources.
• Competition in the market for wound care products.
• Other factors discussed in detail in the company's periodic filings with the Securities and Exchange Commission.

Future Outlook

The company aims to better generate cash flow in support of its ongoing mission to pay down debt out of operating cash flow. Future financial results and business development activities are subject to various risks and uncertainties.

Management Comments

• "This refinancing marks a pivotal step in strengthening Sanuwaves financial position."
• "The significant reduction in our interest rate, the reduction of our overall debt load, and a move to a set of no prepayment penalty terms all position us to better generate cash flow in support of our ongoing mission to pay down our debt out of operating cash flow."
• "We could not ask for a better lender than J.P. Morgan, whose reputation for global leadership in banking needs no introduction. They have already been a great help, and we look forward to working with them going forward."

Industry Context

The filing indicates a strategic move to optimize capital structure, which is a common practice for companies in the healthcare/medical device sector (wound care products) to manage growth, R&D, and operational expenses. Securing a facility with a major bank like J.P. Morgan can also signal increased institutional confidence.

Stakeholder Impact

• Shareholders: Potential for improved financial performance due to lower interest expenses and reduced debt load, leading to better cash flow and potentially higher shareholder value.
• Creditors (J.P. Morgan): New secured position on company assets.
• Previous Creditors (NH Expansion): Full repayment of outstanding debt.
• Employees/Customers/Suppliers: Improved financial stability could indirectly benefit these groups by ensuring continued operations and strategic investments.

Next Steps

• The company will continue its mission to pay down debt out of operating cash flow.

Key Dates

Recommendation

The strategic debt refinancing significantly strengthens Sanuwave's financial position by reducing total debt, lowering interest rates, and removing prepayment penalties. This improved capital structure enhances cash flow generation and operational flexibility, which are strong positive indicators for future profitability and stability. The partnership with J.P. Morgan also adds a layer of institutional confidence. These factors suggest a positive outlook for the stock.

Keywords

SANUWAVE Health, SNWV, Debt Refinancing, Credit Facility, Term Loan, Revolving Credit, JPMorgan Chase, SEC Filing, Financial Restructuring, Wound Care, Corporate Finance, SOFR